BRPI0819932A2 - composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável. - Google Patents
composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável.Info
- Publication number
- BRPI0819932A2 BRPI0819932A2 BRPI0819932A BRPI0819932A BRPI0819932A2 BR PI0819932 A2 BRPI0819932 A2 BR PI0819932A2 BR PI0819932 A BRPI0819932 A BR PI0819932A BR PI0819932 A BRPI0819932 A BR PI0819932A BR PI0819932 A2 BRPI0819932 A2 BR PI0819932A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- nebulizer
- inhaler
- processes
- producing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável a presente invenção diz respeito a métodos de administração pulmonar direta de polipeptídeos, por exemplo, de anticorpos de domínio, e a composições polipeptídicas particulares adequadas para administração pulmonar direta. a invenção também diz respeito ao uso de tais composições na medicina, por exemplo, para o tratamento e diagnóstico de doença pulmonar, por exemplo, para tratar doença pulmonar obstrutiva crônica (copd) e asma.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0724331.4A GB0724331D0 (en) | 2007-12-13 | 2007-12-13 | Compositions for pulmonary delivery |
| BD1272008 | 2008-05-22 | ||
| BD1292008 | 2008-05-22 | ||
| BD1282008 | 2008-05-22 | ||
| BD1302008 | 2008-05-22 | ||
| PCT/GB2008/050400 WO2008149144A2 (en) | 2007-06-06 | 2008-06-03 | Polypeptides, antibody variable domains and antagonists |
| PCT/GB2008/050399 WO2008149143A2 (en) | 2007-06-06 | 2008-06-03 | Methods for selecting protease resistant polypeptides |
| PCT/GB2008/050403 WO2008149146A2 (en) | 2007-06-06 | 2008-06-03 | Polypeptides, antibody variable domains and antagonists |
| PCT/EP2008/067295 WO2009074634A2 (en) | 2007-12-13 | 2008-12-11 | Compositions for pulmonary delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0819932A2 true BRPI0819932A2 (pt) | 2019-07-30 |
Family
ID=61230984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0819932A BRPI0819932A2 (pt) | 2007-12-13 | 2008-12-11 | composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100260853A1 (pt) |
| EP (1) | EP2220115A2 (pt) |
| JP (1) | JP2011506396A (pt) |
| KR (1) | KR20100098697A (pt) |
| CN (1) | CN102131827A (pt) |
| AU (1) | AU2008334605B2 (pt) |
| BR (1) | BRPI0819932A2 (pt) |
| CA (1) | CA2707986A1 (pt) |
| EA (1) | EA201000785A1 (pt) |
| SG (1) | SG185286A1 (pt) |
| TW (1) | TW200938222A (pt) |
| WO (1) | WO2009074634A2 (pt) |
| ZA (1) | ZA201004093B (pt) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ540195A (en) | 2002-11-08 | 2009-01-31 | Ablynx Nv | Stabilized single domain antibodies |
| US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| EP3168618B1 (en) | 2006-04-04 | 2018-11-21 | Singulex, Inc. | Highly sensitive methods for analysis of troponin |
| US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
| SG182170A1 (en) * | 2007-06-06 | 2012-07-30 | Domantis Ltd | Polypeptides, antibody variable domains and antagonists |
| WO2010037818A1 (en) * | 2008-10-02 | 2010-04-08 | Ablynx Nv | Amino acid sequences directed against il-15 and/or the il-15 receptor and polypeptides comprising the same for the treatment of diseases and disorders associated with il-15 mediated signalling |
| EP2358754A1 (en) * | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Ligands that bind il-13 |
| WO2010144358A1 (en) | 2009-06-08 | 2010-12-16 | Singulex, Inc. | Highly sensitive biomarker panels |
| KR20120092611A (ko) * | 2009-09-30 | 2012-08-21 | 글락소 그룹 리미티드 | 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트 |
| CN102753148B (zh) | 2010-02-11 | 2018-01-26 | 埃博灵克斯股份有限公司 | 用于制备气雾剂的方法和组合物 |
| TW201215405A (en) | 2010-08-25 | 2012-04-16 | Hoffmann La Roche | Antibodies against IL-18R1 and uses thereof |
| JP5947802B2 (ja) * | 2010-11-05 | 2016-07-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ミックスモードクロマトグラフィーによる抗体捕捉の最適化方法 |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| MX359070B (es) | 2010-12-01 | 2018-09-13 | Alderbio Holdings Llc | Composiciones anti-ngf y uso de las mismas. |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| KR101875155B1 (ko) * | 2011-05-02 | 2018-07-09 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항-α4β7 항체에 대한 제형 |
| EP2726504A1 (en) * | 2011-05-27 | 2014-05-07 | Dutalys | Antibodies with improved folding stability |
| US9783570B2 (en) | 2011-07-01 | 2017-10-10 | Hoffmann-La Roche Inc. | Method for separation of monomeric polypeptides from aggregated polypeptides |
| US9499612B2 (en) * | 2011-07-27 | 2016-11-22 | Glaxo Group Limited | Antigen binding constructs |
| ES2813432T3 (es) | 2011-08-17 | 2021-03-23 | Glaxo Group Ltd | Proteínas y péptidos modificados |
| AU2014233055B2 (en) | 2013-03-15 | 2018-08-09 | Board Of Regents, The University Of Texas System | Inhibition of pulmonary fibrosis with nutlin-3a and peptides |
| CA2943376C (en) * | 2014-04-03 | 2022-06-14 | Medizinische Hochschule Hannover | Nebulization of immunoglobulin |
| US10670611B2 (en) | 2014-09-26 | 2020-06-02 | Somalogic, Inc. | Cardiovascular risk event prediction and uses thereof |
| WO2016138413A1 (en) * | 2015-02-27 | 2016-09-01 | Board Of Regents, The University Of Texas System | Polypeptide therapeutics and uses thereof |
| BR112021004404A2 (pt) | 2018-09-10 | 2021-08-03 | Lung Therapeutics, Inc. | fragmentos de peptídeos modificados da proteína cav-1 e o uso destes no tratamento de fibrose |
| WO2020109621A1 (en) * | 2018-11-30 | 2020-06-04 | Csl Behring Ag | Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin |
| WO2021152175A1 (en) * | 2020-01-31 | 2021-08-05 | Sanofi | Pulmonary delivery of antibodies |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0162854A1 (en) * | 1983-11-28 | 1985-12-04 | Vortran Corporation | Gas-powered nebulizer |
| EP0710102A1 (en) * | 1993-07-19 | 1996-05-08 | Amgen Inc. | Stabilization of aerosolized proteins |
| US6165463A (en) * | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6858199B1 (en) * | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
| US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| ATE333290T1 (de) * | 2001-05-21 | 2006-08-15 | Injet Digital Aerosols Ltd | Zusammensetzungen für die freisetzung von protein auf dem pulmonalen weg |
| NZ540195A (en) * | 2002-11-08 | 2009-01-31 | Ablynx Nv | Stabilized single domain antibodies |
| US20080312136A1 (en) * | 2003-11-14 | 2008-12-18 | Manzer Durrani | Alpha 1-Antitrypsin Compositions and Treatment Methods Using Such Compositions |
| EP1694314A4 (en) * | 2003-12-04 | 2009-07-01 | Scripps Research Inst | TREATMENT AND PREVENTION OF ASTHMA |
| GB0405634D0 (en) * | 2004-03-12 | 2004-04-21 | Univ Southampton | Anti-virus therapy for respiratory diseases |
| BRPI0518622A2 (pt) * | 2004-12-02 | 2008-12-02 | Domantis Ltd | usos de antagonistas de receptor do tipo 1 de interleucina-1(il-1r1) para a fabricaÇço de um medicamento para o tratamento de uma doenÇa respiratària; composiÇço farmacÊutica que compreende um antagonista do il-1r1 e um veÍculo fisiologicamente aceitÁvel e dispositivo de liberaÇço de medicamento |
| GB0521621D0 (en) * | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| EP1863840A1 (en) * | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Pegylated single-chain insulin |
| US20090324699A1 (en) * | 2005-09-01 | 2009-12-31 | Lena Preswetoff-Morath | Antihistamine-and corticosteroid-containing lipsome composition and its use for the manufacture of medicament for treating rhinitis and related disorders |
| AU2006321367B2 (en) * | 2005-12-01 | 2011-11-03 | Domantis Limited | Competitive domain antibody formats that bind Interleukin 1 Receptor type 1 |
| CA2632417A1 (en) * | 2005-12-06 | 2007-06-14 | Domantis Limited | Ligands that have binding specificity for egfr and/or vegf and methods of use therefor |
| AU2007204879A1 (en) * | 2006-01-11 | 2007-07-19 | Aerovance, Inc. | Methods and compositions for treating asthma in human and non human primates |
| US20110159003A1 (en) * | 2006-01-24 | 2011-06-30 | Domantis Limited | Ligands That Bind Il-4 and/or Il-13 |
| KR20100018040A (ko) * | 2007-06-06 | 2010-02-16 | 도만티스 리미티드 | 프로테아제 내성 폴리펩티드를 선택하는 방법 |
-
2008
- 2008-12-11 CA CA2707986A patent/CA2707986A1/en not_active Abandoned
- 2008-12-11 TW TW097148298A patent/TW200938222A/zh unknown
- 2008-12-11 KR KR1020107015536A patent/KR20100098697A/ko not_active Application Discontinuation
- 2008-12-11 CN CN2008801271605A patent/CN102131827A/zh active Pending
- 2008-12-11 AU AU2008334605A patent/AU2008334605B2/en not_active Ceased
- 2008-12-11 EA EA201000785A patent/EA201000785A1/ru unknown
- 2008-12-11 EP EP08860520A patent/EP2220115A2/en not_active Withdrawn
- 2008-12-11 BR BRPI0819932A patent/BRPI0819932A2/pt not_active IP Right Cessation
- 2008-12-11 WO PCT/EP2008/067295 patent/WO2009074634A2/en active Application Filing
- 2008-12-11 SG SG2012074878A patent/SG185286A1/en unknown
- 2008-12-11 JP JP2010537443A patent/JP2011506396A/ja active Pending
- 2008-12-11 US US12/747,203 patent/US20100260853A1/en not_active Abandoned
-
2010
- 2010-06-08 ZA ZA2010/04093A patent/ZA201004093B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009074634A2 (en) | 2009-06-18 |
| EP2220115A2 (en) | 2010-08-25 |
| JP2011506396A (ja) | 2011-03-03 |
| SG185286A1 (en) | 2012-11-29 |
| AU2008334605B2 (en) | 2013-07-18 |
| WO2009074634A3 (en) | 2010-09-23 |
| ZA201004093B (en) | 2011-11-30 |
| US20100260853A1 (en) | 2010-10-14 |
| EA201000785A1 (ru) | 2011-02-28 |
| TW200938222A (en) | 2009-09-16 |
| KR20100098697A (ko) | 2010-09-08 |
| AU2008334605A1 (en) | 2009-06-18 |
| CN102131827A (zh) | 2011-07-20 |
| CA2707986A1 (en) | 2009-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0819932A2 (pt) | composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável. | |
| EA200901495A1 (ru) | Полипептиды, вариабельные домены антител и антагонисты | |
| BRPI0816784A8 (pt) | Fatores neuro-endócrinos para o tratamento de doenças degenerativas | |
| UY31686A1 (es) | Nueva dosificacion y formulacion | |
| BR112012001297A2 (pt) | conector. | |
| WO2008149144A3 (en) | Polypeptides, antibody variable domains and antagonists | |
| AR067639A1 (es) | Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente | |
| BR112015006571A2 (pt) | composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados | |
| WO2007092772A8 (en) | Protein formulations | |
| EA201190108A1 (ru) | Фармацевтическая композиция для ингаляции | |
| AR073528A1 (es) | Particulas inhalables que comprenden tiotropio | |
| UY31687A1 (es) | Nueva dosificacion y formulacion | |
| MX2011008799A (es) | Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados. | |
| CO6400235A2 (es) | Tensiactivos reconstituidos que tienen propiedades mejoradas | |
| EA201201397A1 (ru) | Ингалятор, содержащий расслаиваемую блистерную упаковку | |
| EA201590019A1 (ru) | Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы | |
| EA201201395A1 (ru) | Кнопочное устройство мундштука ингалятора сухого порошка | |
| CL2008000973A1 (es) | Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma. | |
| NO20073909L (no) | Forstover-formulering | |
| EA201201392A1 (ru) | Кнопочное устройство мундштука ингалятора сухого порошка | |
| EA201201393A1 (ru) | Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка | |
| MX2010012019A (es) | Producto farmaceutico que comprende un antagonista receptor muscarinico y un agonista de adrenoceptor beta2. | |
| BR112017014861A2 (pt) | ?combinação e composição farmacêuticas, inalador de pó seco, uso de uma combinação farmacêutica, e, método para tratamento de um distúrbio pulmonar? | |
| UY30934A1 (es) | Producto farmacéutico combinacion de un antagonista del receptor de quimioquina 1 (ccr1) y un antagonista muscarinico, composiciones farmacéuticas y aplicaciones. | |
| EA201201394A1 (ru) | Ингалятор для доставки лекарственного средства в виде сухого порошка |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 7A, 8A, 9A E 10A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2536 DE 13-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |